A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer.

ABSTRACT:

Background

Despite initial promising results, the IMvigor211 clinical trial failed to demonstrate an overall survival (os) benefit for atezolizumab compared with chemotherapy as second-line treatment for metastatic bladder cancer (mbc). However, given lessened adverse events (aes) and preserved quality of life (qol) with atezolizumab, there might still be investment value. To evaluate that potential value, we conducted a cost-utility analysis (cua) of atezolizumab compared with chemotherapy from the perspective of the Canadian health care payer.

Methods

A partitioned survival model was used to evaluate atezolizumab compared with chemotherapy over a lifetime horizon (5 years). The base-case analysis was conducted for the intention-to-treat (itt) population, with additional sc

SUBMITTER: Parmar A 

PROVIDER: S-EPMC7467791 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature